Literature DB >> 25100669

Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain.

Ermelinda Lomazzo1, Laura Bindila1, Floor Remmers1, Raissa Lerner1, Claudia Schwitter1, Ulrich Hoheisel2, Beat Lutz1.   

Abstract

The occurrence of chronic stress, depression, and anxiety can increase nociception in humans and may facilitate the transition from localized to chronic widespread pain. The mechanisms underlying chronic widespread pain are still unknown, hindering the development of effective pharmacological therapies. Here, we exposed C57BL/6J mice to chronic unpredictable stress (CUS) to investigate how persistent stress affects nociception. Next, mice were treated with multiple intramuscular nerve growth factor (NGF) injections, which induced chronic widespread nociception. Thus, combination of CUS and NGF served as a model where psychophysiological impairment coexists with long-lasting hyperalgesia. We found that CUS increased anxiety- and depression-like behavior and enhanced basal nociception in mice. When co-applied with repeated NGF injections, CUS elicited a sustained long-lasting widespread hyperalgesia. In order to evaluate a potential therapeutic strategy for the treatment of chronic pain associated with stress, we hypothesized that the endocannabinoid system (ECS) may represent a target signaling system. We found that URB597, an inhibitor of the anandamide-degrading enzyme fatty acid amide hydrolase (FAAH), and JZL184, an inhibitor of the 2-arachidonoyl glycerol-degrading enzyme monoacylglycerol lipase (MAGL), increased eCB levels in the brain and periphery and were both effective in reducing CUS-induced anxiety measured by the light-dark test and CUS-induced thermal hyperalgesia. Remarkably, the long-lasting widespread hyperalgesia induced by combining CUS and NGF was effectively reduced by URB597, but not by JZL184. Simultaneous inhibition of FAAH and MAGL did not improve the overall therapeutic response. Therefore, our findings indicate that enhancement of anandamide signaling with URB597 is a promising pharmacological approach for the alleviation of chronic widespread nociception in stress-exposed mice, and thus, it could represent a potential treatment strategy for chronic pain associated with neuropsychiatric disorders in humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25100669      PMCID: PMC4443964          DOI: 10.1038/npp.2014.198

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.

Authors:  Sudeshna Ghosh; Laura E Wise; Yugang Chen; Ramesh Gujjar; Anu Mahadevan; Benjamin F Cravatt; Aron H Lichtman
Journal:  Life Sci       Date:  2012-06-28       Impact factor: 5.037

2.  Local pain and spreading hyperalgesia induced by intramuscular injection of nerve growth factor are not reduced by local anesthesia of the muscle.

Authors:  Renate Karin Herren Gerber; Hongling Nie; Lars Arendt-Nielsen; Michele Curatolo; Thomas Graven-Nielsen
Journal:  Clin J Pain       Date:  2011 Mar-Apr       Impact factor: 3.442

3.  Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Authors:  Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2013-02-14       Impact factor: 4.030

4.  Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain.

Authors:  Maulik D Jhaveri; Denise Richardson; David A Kendall; David A Barrett; Victoria Chapman
Journal:  J Neurosci       Date:  2006-12-20       Impact factor: 6.167

5.  Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation.

Authors:  Daniel K Nomura; Bradley E Morrison; Jacqueline L Blankman; Jonathan Z Long; Steven G Kinsey; Maria Cecilia G Marcondes; Anna M Ward; Yun Kyung Hahn; Aron H Lichtman; Bruno Conti; Benjamin F Cravatt
Journal:  Science       Date:  2011-10-20       Impact factor: 47.728

6.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

Review 7.  Peripheral gating of pain signals by endogenous lipid mediators.

Authors:  Daniele Piomelli; Oscar Sasso
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

8.  Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Authors:  S G Kinsey; J Z Long; S T O'Neal; R A Abdullah; J L Poklis; D L Boger; B F Cravatt; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2009-06-05       Impact factor: 4.030

9.  Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice.

Authors:  Sarah Dubreucq; Isabelle Matias; Pierre Cardinal; Martin Häring; Beat Lutz; Giovanni Marsicano; Francis Chaouloff
Journal:  Neuropsychopharmacology       Date:  2012-03-21       Impact factor: 7.853

10.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.

Authors:  Jonathan Z Long; Weiwei Li; Lamont Booker; James J Burston; Steven G Kinsey; Joel E Schlosburg; Franciso J Pavón; Antonia M Serrano; Dana E Selley; Loren H Parsons; Aron H Lichtman; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2008-11-23       Impact factor: 15.040

View more
  50 in total

1.  The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Authors:  Mano Aliczki; Istvan Barna; Ibolya Till; Maria Baranyi; Beata Sperlagh; Steven R Goldberg; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2016-01-26       Impact factor: 4.530

Review 2.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

Review 3.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 4.  Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.

Authors:  Gernot F Grabner; Robert Zimmermann; Rudolf Schicho; Ulrike Taschler
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

5.  Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.

Authors:  Nicholas S Adamson Barnes; Vanessa A Mitchell; Nicholas P Kazantzis; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2015-12-01       Impact factor: 8.739

6.  Stress-induced modulation of endocannabinoid signaling leads to delayed strengthening of synaptic connectivity in the amygdala.

Authors:  Farhana Yasmin; Roberto Colangeli; Maria Morena; Sarah Filipski; Mario van der Stelt; Quentin J Pittman; Cecilia J Hillard; G Campbell Teskey; Bruce S McEwen; Matthew N Hill; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

7.  A runner's high depends on cannabinoid receptors in mice.

Authors:  Johannes Fuss; Jörg Steinle; Laura Bindila; Matthias K Auer; Hartmut Kirchherr; Beat Lutz; Peter Gass
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

Review 8.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 9.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

Review 10.  The Role of the Endocannabinoid System in the Brain-Gut Axis.

Authors:  Keith A Sharkey; John W Wiley
Journal:  Gastroenterology       Date:  2016-04-29       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.